dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Efstathiou, E. | en |
dc.contributor.author | Farmakis, D. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Fountzilas, George | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Efstathiou, E. | en |
dc.creator | Farmakis, D. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.date.accessioned | 2018-06-22T09:54:23Z | |
dc.date.available | 2018-06-22T09:54:23Z | |
dc.date.issued | 2006 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42332 | |
dc.description.abstract | Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). Patients and methods.: A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. Results.: One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45% (complete response 25%) (95% CI, 23.1% to 68.5%) and 81% (complete response 46%) (95% CI, 67.4% to 91.1%) for sEOC. The overall response rate was significantly higher for sEOC (P = 0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients (P = 0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95% CI 11.7 to 38.5 months] versus 49.1 months [95% CI 36.5 to 61.6 months], P = 0.141, 12.0 months [95% CI 6.5 to 17.3 months] versus 18.0 months [95% CI 14.7 to 21.6 months], P = 0.384, respectively). Conclusion.: Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents. © 2006 Elsevier Inc. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Gynecologic oncology | en |
dc.subject | Article | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Cancer patient | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Priority journal | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Cisplatin | en |
dc.subject | Platinum | en |
dc.subject | Cancer staging | en |
dc.subject | Survival rate | en |
dc.subject | Overall survival | en |
dc.subject | Outcome assessment | en |
dc.subject | Survival | en |
dc.subject | Carboplatin | en |
dc.subject | Survival time | en |
dc.subject | Therapy effect | en |
dc.subject | Treatment response | en |
dc.subject | Paclitaxel | en |
dc.subject | Cancer regression | en |
dc.subject | Combined modality therapy | en |
dc.subject | Comparative study | en |
dc.subject | Clinical protocol | en |
dc.subject | Epirubicin | en |
dc.subject | Doxorubicin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Clear cell | en |
dc.subject | Clear cell carcinoma | en |
dc.subject | Clear-cell epithelial ovarian cancer | en |
dc.subject | Cystadenocarcinoma | en |
dc.subject | Platinum-based chemotherapy | en |
dc.subject | Response | en |
dc.subject | Serous | en |
dc.title | Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ygyno.2005.12.038 | |
dc.description.volume | 102 | |
dc.description.issue | 2 | |
dc.description.startingpage | 285 | |
dc.description.endingpage | 291 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |